Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

Kacper Karaban; Dorota Słupik; Aleksandra Reda; Magdalena Gajewska; Bartosz Rolek; Josip A. Borovac; Panteleimon E. Papakonstantinou; Dario Bongiovanni; Hanne Ehrlinder; William A. E. Parker; Aleksander Siniarski; Aleksandra Gąsecka

doi:10.1016/j.cpcardiol.2023.102127

Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

Kacper Karaban, Dorota Słupik, Aleksandra Reda, Magdalena Gajewska, Bartosz Rolek, Josip A. Borovac, Panteleimon E. Papakonstantinou, Dario Bongiovanni, Hanne Ehrlinder, William A. E. Parker, Aleksander Siniarski, Aleksandra Gąsecka

Laboratory Specialized Diagnostics & Research (AMC)

Research output: Contribution to journal › Review article › Academic › peer-review

2 Citations (Scopus)

Abstract

Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.

Original language	English
Article number	102127
Journal	Current Problems in Cardiology
Volume	49
Issue number	1
DOIs	https://doi.org/10.1016/j.cpcardiol.2023.102127
Publication status	Published - 1 Jan 2024

Access to Document

10.1016/j.cpcardiol.2023.102127

Cite this

Karaban, K., Słupik, D., Reda, A., Gajewska, M., Rolek, B., Borovac, J. A., Papakonstantinou, P. E., Bongiovanni, D., Ehrlinder, H., Parker, W. A. E., Siniarski, A., & Gąsecka, A. (2024). Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction. Current Problems in Cardiology, 49(1), Article 102127. https://doi.org/10.1016/j.cpcardiol.2023.102127

@article{c6de48e7ce9f43028a2e63057490108e,

title = "Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction",

abstract = "Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.",

author = "Kacper Karaban and Dorota S{\l}upik and Aleksandra Reda and Magdalena Gajewska and Bartosz Rolek and Borovac, {Josip A.} and Papakonstantinou, {Panteleimon E.} and Dario Bongiovanni and Hanne Ehrlinder and Parker, {William A. E.} and Aleksander Siniarski and Aleksandra G{\c a}secka",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/j.cpcardiol.2023.102127",

language = "English",

volume = "49",

journal = "Current Problems in Cardiology",

issn = "0146-2806",

publisher = "Mosby Inc.",

number = "1",

}

Karaban, K, Słupik, D, Reda, A, Gajewska, M, Rolek, B, Borovac, JA, Papakonstantinou, PE, Bongiovanni, D, Ehrlinder, H, Parker, WAE, Siniarski, A & Gąsecka, A 2024, 'Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction', Current Problems in Cardiology, vol. 49, no. 1, 102127. https://doi.org/10.1016/j.cpcardiol.2023.102127

TY - JOUR

T1 - Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

AU - Karaban, Kacper

AU - Słupik, Dorota

AU - Reda, Aleksandra

AU - Gajewska, Magdalena

AU - Rolek, Bartosz

AU - Borovac, Josip A.

AU - Papakonstantinou, Panteleimon E.

AU - Bongiovanni, Dario

AU - Ehrlinder, Hanne

AU - Parker, William A. E.

AU - Siniarski, Aleksander

AU - Gąsecka, Aleksandra

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.

AB - Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.

UR - http://www.scopus.com/inward/record.url?scp=85177842678&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2023.102127

DO - 10.1016/j.cpcardiol.2023.102127

M3 - Review article

C2 - 37802171

SN - 0146-2806

VL - 49

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

IS - 1

M1 - 102127

ER -

Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

Abstract

Access to Document

Other files and links

Cite this